

Suitability Petition Completeness Assessment Correspondence

Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, DC 20005-5929 Attn: Kurt R. Karst

Sent via email to: KKarst@hpm.com

Docket No. FDA-2024-P-2885

Dear Kurt R. Karst:

This is in reference to your petition received on June 17, 2024, by the U.S. Food and Drug Administration (FDA or Agency), requesting permission, in accordance with 21 C.F.R. §314.93(b), to submit an Abbreviated New Drug Application (ANDA) for the following drug product: Olaparib Tablets, 200 mg and 300 mg. The petition was examined for initial completeness (i.e. Completeness Assessment) under CFR 10.30 and the Agency has made a threshold determination that the petition is complete.

This petition is subject to the provisions of the Generic Drugs User Fee Amendments of 2022 (GDUFA III) whereby any suitability petitions submitted in FY 2024-2027 will receive a goal date of 6 months after the completeness assessment. The GDUFA goal date for review of this petition is January 2, 2025.

If you have any questions, contact ANDAFiling@fda.hhs.gov.

A copy of this letter will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

{See appended electronic signature page}

Julia Lee, Pharm.D.
Deputy Division Director
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Digitally signed by Julia Lee Date: 7/02/2024 07:43:53AM

GUID: 50af9fa80005f49daa5581f441322977